BioLargo Inc (OTCMKTS:BLGO) announced Tuesday that Sunworks Farm wants a commercial trial of its Advanced Oxidation System (AOS) to manage and treat water and wastewater on the property, the first-ever commercial trial for the technology.
In a statement, the firm said its subsidiary BioLargo Water has been asked by the owners of the Alberta-based farm to submit a proposal to install the system. Sunworks raises certified organic chicken, turkey, beef, pork and eggs.
The company said the Sunworks project will mark a pivotal moment in the commercialization of BioLargo’s proprietary technology.
BioLargo’s AOS technology combines highly energized iodine molecules with cutting-edge filtration materials to destroy bacteria and dismantle soluble organic contaminants.
“Our experience with BioLargo Water’s pre-commercial pilot for their AOS water treatment system has been exceptional,” said Ron and Sheila Hamilton, owners of Sunworks Farm, in the statement.
“Their technology clearly works, and their team is a pleasure to work with. We believe that the AOS will enable producers like us to manage water and wastewater in the most environmentally sensitive and economical way possible,” they added.
The couple said they have asked BioLargo Water to develop a proposal for a full-scale commercial trial for AOS and an accompanying proprietary treatment train to manage all water and wastewater at the farm, with the aim of achieving nearly 100% water reuse.
“We look forward to working hand-in-hand with their team to establish their technology as part of a new benchmark for environmental stewardship in water conservation in the North American livestock industry,” they added.
BioLargo Water said its staff are preparing a proposal for the commercial trial of the AOS unit and treatment train, and expects to deliver it to Sunworks soon.
The parent company, based in Westminster, California, has developed several innovative and patented products targeted at three markets: water and wastewater treatment, industrial odor and volatile organic compounds elimination, and advanced wound care.
BioLargo’s stock recently traded 6% higher to $0.33 a share on the OTC Market.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham